XML 141 R47.htm IDEA: XBRL DOCUMENT
v3.20.4

Summary of Significant Accounting Policies - Significant Customers (Details) - Customer Concentration Risk | 12 Months Ended
--- | ---
Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018
Revenue | Merck |  |  |
Concentration Risk [Line Items] |  |  |
Concentration risk, percentage |  | 61.00% | 49.00%
Revenue | BARDA |  |  |
Concentration Risk [Line Items] |  |  |
Concentration risk, percentage | 65.00% | 13.00% |
Revenue | Vertex |  |  |
Concentration Risk [Line Items] |  |  |
Concentration risk, percentage |  | 10.00% |
Revenue | AstraZeneca |  |  |
Concentration Risk [Line Items] |  |  |
Concentration risk, percentage |  |  | 34.00%
Revenue | U.S. Government (excluding BARDA) |  |  |
Concentration Risk [Line Items] |  |  |
Concentration risk, percentage | 24.00% |  |
Accounts Receivable | Merck |  |  |
Concentration Risk [Line Items] |  |  |
Concentration risk, percentage |  | 13.00% |
Accounts Receivable | BARDA |  |  |
Concentration Risk [Line Items] |  |  |
Concentration risk, percentage | 22.00% | 54.00% |
Accounts Receivable | Vertex |  |  |
Concentration Risk [Line Items] |  |  |
Concentration risk, percentage |  | 17.00% |
Accounts Receivable | European Commission |  |  |
Concentration Risk [Line Items] |  |  |
Concentration risk, percentage | 28.00% |  |
Accounts Receivable | United Kingdom Government |  |  |
Concentration Risk [Line Items] |  |  |
Concentration risk, percentage | 11.00% |  |
Accounts Receivable | South Korea Government |  |  |
Concentration Risk [Line Items] |  |  |
Concentration risk, percentage | 24.00% |  |

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_ConcentrationRiskLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=121572278&loc=d3e13531-108611 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592 + Details
Name: | us-gaap_ConcentrationRiskPercentage1
Namespace Prefix: | us-gaap_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_MajorCustomersAxis=mrna_MerckMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_MajorCustomersAxis=mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_MajorCustomersAxis=mrna_VertexMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_MajorCustomersAxis=mrna_AstraZenecaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_MajorCustomersAxis=mrna_USGovermentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_MajorCustomersAxis=mrna_EuropeanCommissionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_MajorCustomersAxis=mrna_UnitedKingdomGovernmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_MajorCustomersAxis=mrna_SouthKoreaGovernmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |